GET DAILY SIGNALSSCYNEXIS (SCYX) Q3 2026 Earnings Preview: Pipeline Progress and Cash Position Take Center Stage
Key Takeaways
- SCYNEXIS, Inc. (SCYX) is expected to report third quarter 2026 results in November 2026, with most trackers pointing to a release around November 10–11.
- Wall Street consensus calls for a net loss of $0.72 per share on roughly $0.13 million in revenue.
- A year earlier, in Q3 2025, the company posted a loss of $1.36 per share on revenue of about $0.33 million.
- In its most recent quarter (Q2 2026), SCYNEXIS swung to a GAAP profit of $0.63 per share on $235,000 in revenue, helped by non-operating gains.
- The key narrative around this report is the company's investigational pipeline, particularly the SCY-770 program, plus its cash position and research spending.
Placing the Earnings in Context
SCYNEXIS is a clinical-stage biotechnology company whose lead asset, SCY-770, is being developed for autosomal dominant polycystic kidney disease (ADPKD), a rare and progressive kidney condition. For a pre-revenue-stage drug developer, the quarterly earnings report is less about traditional sales and more about cash runway, research and development (R&D) spending, and clinical progress. Recent quarters have been volatile: the company posted a $2.00-per-share profit in Q4 2025 on milestone-driven revenue of $18.65 million, then swung to a loss in Q1 2026 before a one-time gain lifted Q2 2026 back to a profit. Investors will look past that lumpiness and focus on the pipeline update. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What the Consensus Numbers Show
For the third quarter of 2026, the Wall Street consensus estimate is a loss of $0.72 per share, with revenue expected around $0.13 million. That compares with a loss of $1.36 per share and revenue of about $0.33 million in the same period a year ago. Analysts generally expect continued operating losses, as revenue for this stage of the company is minimal and milestone-dependent rather than recurring.
Investors will be watching several metrics beyond the headline numbers. First, the cash and equivalents balance, which determines how long the company can fund development without raising capital. Second, R&D expense, which signals the pace of investment in the SCY-770 program. Third, any update on Phase 1 topline data for SCY-770, which management had indicated was expected in the third quarter. Historically, SCYNEXIS has beaten consensus earnings per share (EPS) in six of its last eight quarters, but results have been heavily influenced by non-operating items.
Market Sentiment Heading Into the Report
Sentiment heading into SCYNEXIS's third-quarter report is cautious. The stock has been volatile over the past year, reflecting the company's transition and the unpredictable, milestone-driven nature of its revenue. A key risk is that the operating loss widens faster than expected, raising concerns about cash runway. Investors are also sensitive to any delay or setback in the SCY-770 clinical timeline, since pipeline progress is the primary driver of long-term value for a development-stage biotech. A clean Phase 1 data readout and a stable cash position would likely be viewed favorably, while an unexpected financing need or slower-than-expected development progress could weigh on the shares.
Key Items to Monitor Beyond the Numbers
Looking beyond the quarterly print, the most important catalyst is the SCY-770 Phase 1 data readout. Topline results will help investors gauge safety, tolerability, and early signs of the drug's profile in ADPKD. Any signal that supports advancing into later-stage trials would be a significant development for the company's pipeline.
Cash management will be equally important. As a clinical-stage company with limited recurring revenue, SCYNEXIS's ability to fund its programs without excessive dilution is a central concern. Investors should monitor the cash and equivalents balance and management's commentary on runway, which typically extends how far current resources are expected to carry operations.
Finally, watch for any updates on potential milestone payments or collaboration activity. The company's revenue has historically been lumpy, and non-recurring items can swing quarterly results sharply. Investors should focus on the underlying operating expense trend and clinical milestones rather than headline earnings volatility when interpreting this report and the quarters ahead.
How Tickeron’s AI Tools Fit Into My Research
In my own workflow, I regularly use Tickeron’s AI Screener to cross-check biotech names like SCYX against peers on technical patterns and fundamentals. It helps surface signals that complement the earnings-driven view without replacing fundamental analysis. This keeps my process efficient when tracking development-stage companies where clinical updates matter most.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SCYX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for SCYX turned positive on October 28, 2026. Looking at past instances where SCYX's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SCYX's RSI Indicator exited the oversold zone, 30 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 63 cases where SCYX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on SCYX as a result. In 56 of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +4.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where SCYX advanced for three days, in 190 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
SCYX moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCYX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
SCYX broke above its upper Bollinger Band on October 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.571) is normal, around the industry mean (7.659). P/E Ratio (-4.220) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.647) is also within normal values, averaging (181.047).
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. SCYX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCYX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in discovery, development and commercialization of novel anti infectives
Industry PharmaceuticalsGeneric
Advertisement